GPC3-Targeted PET/CT in Hepatocellular Carcinoma

Inclusion Criteria: * Adult patients (aged 18 years or older); * Patients with suspected, newly diagnosed, or previously treated hepatocellular carcinoma(supporting evidence may include imaging findings and pathology report); * Patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee. * Estimated life expectancy of more than 3 months, as assessed by the investigator, and ability to comply with study procedures and scheduled visits; Exclusion Criteria: * Lack of contrast-enhanced liver MRI or an interval of more than 14 days between GPC3-targeted PET/CT and contrast-enhanced liver MRI. * Receipt of antitumor treatment between imaging examinations. * The inability or unwillingness of the research participant or legal representative to provide written informed consent. * Inability to complete PET/CT imaging.